Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) was up 2.6% during trading on Wednesday . The stock traded as high as $0.31 and last traded at $0.31. Approximately 2,254 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 21,155 shares. The stock had previously closed at $0.31.
Panbela Therapeutics Trading Up 2.6 %
The firm has a market cap of $1.52 million, a P/E ratio of 0.00 and a beta of 1.33. The business’s 50-day moving average is $0.35 and its two-hundred day moving average is $0.35.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Featured Articles
- Five stocks we like better than Panbela Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Are Tariffs Threatening Disney’s Comeback Story?
- What is MarketRank™? How to Use it
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
